FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046338595> ?p ?o ?g. }

• W3046338595 endingPage "617" @default.
• W3046338595 startingPage "615" @default.
• W3046338595 abstract "The recent publication by Choudhury and Mukherjee1 in this journal depicted the interactions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein with the cell surface Toll-like receptors (TLRs) which is a relevant addition to the existing knowledge of coronavirus disease 2019 (COVID-19) immunobiology. In this fast-spreading pandemic situation of COVID-19, more than six lakhs peoples have died till date. The appropriate therapeutic treatment strategy, drug, or vaccine is still not available. Current clinical data manifests that the severity is due to the cytokine storm and overt immuno-pathogenesis, causing inflammation in the lungs particularly at the alveolar tissue.2, 3 Activation of the human innate immune cells (macrophages, dendritic cells) through the binding of PAMP from SARS-Cov-2 to cell surface TLRs have been demonstrated to be a vital mediator of COVID-19 immunopathogenesis.4 Signaling pathways originated from TLR4 and TLR5 leading to the activation of mitogen-activated protein kinases and/or nuclear factor-κB induces the expression of proinflammatory cytokines.5 Particularly in SARS-CoV-2 infection, major immunopathological consequences leading to death have resulted from the interaction of the SARS-CoV-2 antigens and human TLRs.6, 7 Precisely, viral spike protein binds with the extracellular domain of various TLRs including TLR1, TLR4, and TLR6, with the strongest binding with TLR4.1 Considering the immense importance in the disease biology of COVID-19, TLR-SARS-CoV-2 interaction appears to be a suitable target for the conception of appropriate therapeutic strategy against the pandemic. Being the crucial innate immune sensors and critical mediators of human immunity, manipulation of the activity of TLRs for restoring immune-homeostasis in patients with COVID-19 is currently under consideration for developing effective therapeutics.6 Applying TLR-agonists (eg, PUL-042) for pre-stimulation of immune repertoires are currently aimed to present as possible prophylaxis for the uninfected individuals while TLR-antagonists (eg, M5049, hydroxychloroquine sulfate, imiquimod) are expected to cease the overt proinflammatory milieu (cytokine storm) in the infected symptomatic patients with COVID-19 (as summarized in Figure 1). Most of the TLR antagonists can competitively inhibit the binding of spike protein/other viral PAMP to TLR and dampens the expression of the proinflammatory cytokines like interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor-α. A number of TLR-targeting immunotherapeutics are presently undergoing through different phases of the clinical trial are presented in Table 1. It is noteworthy to mention that in the recent past several TLR antagonists (eg, Eritoran, TAK-242, NI-0101, and SPA4) have already been explored successfully for reducing the inflammatory responses associated cancer, rheumatoid arthritis and other inflammatory diseases of human.8, 9 It is quite obvious that targeted manipulation of human TLRs also possesses the chance of unexpected outcomes. For example, inhibitors of TLRs could suppress interferon-related responses which could increase the viral load. Therefore, suitable optimization of dose and duration of treatment are particularly important for the success of TLR-targeted therapy. Most of the TLR-antagonists currently undergoing through clinical trials are aiming to reduce the detrimental effects of the immune system by lowering the inflammatory mediators without causing a drastic change in their basal levels to maintain the immune homeostasis. Intriguingly, a number of recent studies have also enumerated the design of multi-epitope (B-cell and T-cell epitopes) peptide vaccines which can strongly bind to human TLR3 and/or TLR5 and can elicit an adequate level of immune response to circumvent the infection of SARS-CoV-2.10, 11 Interestingly, these vaccines are also expected to shape both B- and T-cell mediated immune responses. All these studies do indicate selective targeting of human TLRs using immuno-pharmacological agents and/or vaccines as promising options to stimulate the immune system of uninfected individuals or reducing the fatal “cytokine storm” in infected individuals, especially alleviating the inflammation of alveolar tissue, reducing fever and clinical refinement. However, validation of these new therapeutics is currently underway at various phases of clinical and we shall have to wait for a few more months to cheer the success of TLR-targeted intervention approaches in curing the COVID-19 pandemic." @default.
• W3046338595 created "2020-08-07" @default.
• W3046338595 creator A5032807204 @default.
• W3046338595 creator A5042962895 @default.
• W3046338595 creator A5059524572 @default.
• W3046338595 date "2020-08-13" @default.
• W3046338595 modified "2023-10-18" @default.
• W3046338595 title "Targeting human TLRs to combat COVID‐19: A solution?" @default.
• W3046338595 cites W2287500273 @default.
• W3046338595 cites W2513389639 @default.
• W3046338595 cites W2944795429 @default.
• W3046338595 cites W3007407747 @default.
• W3046338595 cites W3013853564 @default.
• W3046338595 cites W3016771699 @default.
• W3046338595 cites W3020799381 @default.
• W3046338595 cites W3023140107 @default.
• W3046338595 cites W3023982717 @default.
• W3046338595 cites W3036639772 @default.
• W3046338595 doi "https://doi.org/10.1002/jmv.26387" @default.
• W3046338595 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7436140" @default.
• W3046338595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32749702" @default.
• W3046338595 hasPublicationYear "2020" @default.
• W3046338595 type Work @default.
• W3046338595 sameAs 3046338595 @default.
• W3046338595 citedByCount "78" @default.
• W3046338595 countsByYear W30463385952020 @default.
• W3046338595 countsByYear W30463385952021 @default.
• W3046338595 countsByYear W30463385952022 @default.
• W3046338595 countsByYear W30463385952023 @default.
• W3046338595 crossrefType "journal-article" @default.
• W3046338595 hasAuthorship W3046338595A5032807204 @default.
• W3046338595 hasAuthorship W3046338595A5042962895 @default.
• W3046338595 hasAuthorship W3046338595A5059524572 @default.
• W3046338595 hasBestOaLocation W30463385951 @default.
• W3046338595 hasConcept C104317684 @default.
• W3046338595 hasConcept C136449434 @default.
• W3046338595 hasConcept C142724271 @default.
• W3046338595 hasConcept C150194340 @default.
• W3046338595 hasConcept C159047783 @default.
• W3046338595 hasConcept C164027704 @default.
• W3046338595 hasConcept C190727270 @default.
• W3046338595 hasConcept C203014093 @default.
• W3046338595 hasConcept C2776070231 @default.
• W3046338595 hasConcept C2776914184 @default.
• W3046338595 hasConcept C2777648638 @default.
• W3046338595 hasConcept C2779134260 @default.
• W3046338595 hasConcept C2779138994 @default.
• W3046338595 hasConcept C2779559532 @default.
• W3046338595 hasConcept C3008058167 @default.
• W3046338595 hasConcept C524204448 @default.
• W3046338595 hasConcept C54355233 @default.
• W3046338595 hasConcept C71924100 @default.
• W3046338595 hasConcept C86803240 @default.
• W3046338595 hasConcept C8891405 @default.
• W3046338595 hasConceptScore W3046338595C104317684 @default.
• W3046338595 hasConceptScore W3046338595C136449434 @default.
• W3046338595 hasConceptScore W3046338595C142724271 @default.
• W3046338595 hasConceptScore W3046338595C150194340 @default.
• W3046338595 hasConceptScore W3046338595C159047783 @default.
• W3046338595 hasConceptScore W3046338595C164027704 @default.
• W3046338595 hasConceptScore W3046338595C190727270 @default.
• W3046338595 hasConceptScore W3046338595C203014093 @default.
• W3046338595 hasConceptScore W3046338595C2776070231 @default.
• W3046338595 hasConceptScore W3046338595C2776914184 @default.
• W3046338595 hasConceptScore W3046338595C2777648638 @default.
• W3046338595 hasConceptScore W3046338595C2779134260 @default.
• W3046338595 hasConceptScore W3046338595C2779138994 @default.
• W3046338595 hasConceptScore W3046338595C2779559532 @default.
• W3046338595 hasConceptScore W3046338595C3008058167 @default.
• W3046338595 hasConceptScore W3046338595C524204448 @default.
• W3046338595 hasConceptScore W3046338595C54355233 @default.
• W3046338595 hasConceptScore W3046338595C71924100 @default.
• W3046338595 hasConceptScore W3046338595C86803240 @default.
• W3046338595 hasConceptScore W3046338595C8891405 @default.
• W3046338595 hasIssue "2" @default.
• W3046338595 hasLocation W30463385951 @default.
• W3046338595 hasLocation W30463385952 @default.
• W3046338595 hasOpenAccess W3046338595 @default.
• W3046338595 hasPrimaryLocation W30463385951 @default.
• W3046338595 hasRelatedWork W1513368991 @default.
• W3046338595 hasRelatedWork W2057980850 @default.
• W3046338595 hasRelatedWork W2078378773 @default.
• W3046338595 hasRelatedWork W2136469540 @default.
• W3046338595 hasRelatedWork W2141330728 @default.
• W3046338595 hasRelatedWork W26362841 @default.
• W3046338595 hasRelatedWork W2903189655 @default.
• W3046338595 hasRelatedWork W2917832881 @default.
• W3046338595 hasRelatedWork W3168815991 @default.
• W3046338595 hasRelatedWork W4224862991 @default.
• W3046338595 hasVolume "93" @default.
• W3046338595 isParatext "false" @default.
• W3046338595 isRetracted "false" @default.
• W3046338595 magId "3046338595" @default.
• W3046338595 workType "article" @default.